A Continuation from post 4/29/07: Today;
DUSA Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Levulan® (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the treatment of esophageal dysplasia. This disease occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. The incidence of esophageal cancer is one of the most rapidly growing in the U.S., with more than 11,000 new diagnoses each year. Patients diagnosed with high grade dysplasia are at high risk for developing esophageal cancer and currently have limited treatment options.
Note that this is not a current indication from the FDA warning letter described on 29 April. Not even a skin lesion. Barrett's is a direct link to smoking, so this is big time news. More on how the mechanism of photoactivity treatment of dysplasia soon.
skip to main |
skip to sidebar
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
A Scientific Interpretation of Stock and Clinical Trial Data that's easy to understand
Check out Whatisthatdrug.com--new posts daily on drugs advertised in current media
Focal Adhesions: How cells crawl along
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
About Me
- Science Food Logic
- I have wet bench research experience in pharmacology, biochemistry and cell biology. Further, I have clinical research experience in ophthalmology, pathology and immunology. I am employed full time as a research scientist in the pharmaceutical industry. In my off time, I enjoy creating fine dining dishes as well as 20 minute meals that taste like fine dining. I like to teach both professionally and in the kitchen.